- Trials with a EudraCT protocol (419)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
419 result(s) found for: Pain Intensity Assessment.
Displaying page 19 of 21.
| EudraCT Number: 2007-004360-44 | Sponsor Protocol Number: VAC034 | Start Date*: 2008-04-29 |
| Sponsor Name:University of Oxford | ||
| Full Title: Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP | ||
| Medical condition: Malaria | ||
| Disease: | ||
| Population Age: | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-004963-68 | Sponsor Protocol Number: 26866138-LUC-2006 | Start Date*: 2007-10-16 | |||||||||||
| Sponsor Name:Prof Vassilis Georgoulias | |||||||||||||
| Full Title: A Phase II, Open-Label Trial of Bortezomib (Velcade®) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | |||||||||||||
| Medical condition: First Line treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004940-27 | Sponsor Protocol Number: AIC316-03-II-01(Phase3) | Start Date*: 2022-01-05 |
| Sponsor Name:AiCuris Anti-infective Cures GmbH | ||
| Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ... | ||
| Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-011577-32 | Sponsor Protocol Number: LUMI/09/Fro+Dex-Mig/001 | Start Date*: 2009-05-29 | ||||||||||||||||
| Sponsor Name:LUSOFARMACO | ||||||||||||||||||
| Full Title: Comparison between frovatriptan plus different treatment regimens of dexketoprofen (25 mg and 37.5 mg) and frovatriptan alone in the acute treatment of migraine without aura and migraine with aura ... | ||||||||||||||||||
| Medical condition: migraine with or without aura | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-005055-17 | Sponsor Protocol Number: MRZ60201_3071_1 | Start Date*: 2013-09-26 | |||||||||||
| Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
| Full Title: Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of c... | |||||||||||||
| Medical condition: Lower limb and combined lower limb and upper limb spasticity due to cerebral palsy | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) EE (Completed) SK (Completed) CZ (Completed) Outside EU/EEA FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-005991-41 | Sponsor Protocol Number: OPTUK MSPP PRO002 | Start Date*: 2007-03-12 | |||||||||||
| Sponsor Name:OptiNose UK Ltd. | |||||||||||||
| Full Title: A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine. | |||||||||||||
| Medical condition: Acute Treatment of Migraine with or without Aura | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001122-22 | Sponsor Protocol Number: BLUEPAT_FNUSA_2021 | Start Date*: 2021-04-20 | |||||||||||
| Sponsor Name:Fakultní nemocnice u sv. Anny v Brně | |||||||||||||
| Full Title: Subpleural lung nodules marking with blue dye substance and contrast agent under CT-guided control with subsequent videothoracoscopic wedge resection: prospective randomized study. | |||||||||||||
| Medical condition: Focal pulmonary lesions | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003002-27 | Sponsor Protocol Number: MIT-Es001-C303 | Start Date*: 2020-10-14 | |||||||||||
| Sponsor Name:Estetra SRL | |||||||||||||
| Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an... | |||||||||||||
| Medical condition: Contraception | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
| Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004664-18 | Sponsor Protocol Number: NEOD001-OLE251 | Start Date*: 2017-08-08 | |||||||||||
| Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
| Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO) | |||||||||||||
| Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201 | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003680-10 | Sponsor Protocol Number: AROAPOC3-3001 | Start Date*: 2022-01-13 | |||||||||||
| Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome | |||||||||||||
| Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003656-35 | Sponsor Protocol Number: E7389-G000-211 | Start Date*: 2006-03-14 |
| Sponsor Name:Eisai Limited | ||
| Full Title: A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to... | ||
| Medical condition: Locally advanced or metastatic breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-001060-35 | Sponsor Protocol Number: CLR_18_07 | Start Date*: 2018-08-29 | |||||||||||||||||||||
| Sponsor Name:Sun Pharmaceutical Industries Limited (SPIL) | |||||||||||||||||||||||
| Full Title: A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab | |||||||||||||||||||||||
| Medical condition: Psoriatic Arthritis (PsA) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2019-003577-25 | Sponsor Protocol Number: 1907V921F | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Shionogi B.V. | |||||||||||||
| Full Title: A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment w... | |||||||||||||
| Medical condition: Opioid induced constipation | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Prematurely Ended) IT (Completed) NL (Prematurely Ended) BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005092-13 | Sponsor Protocol Number: MO42623 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED ≥ 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVI... | |||||||||||||
| Medical condition: Severe or Moderate Hemophilia A | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HU (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002293-41 | Sponsor Protocol Number: AB12005 | Start Date*: 2015-07-02 | |||||||||||
| Sponsor Name:AB Science | |||||||||||||
| Full Title: A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to g... | |||||||||||||
| Medical condition: Non resectable locally advanced or metastatic pancreatic cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) DE (Prohibited by CA) SK (Prohibited by CA) GR (Completed) GB (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001649-38 | Sponsor Protocol Number: 19379A | Start Date*: 2022-06-24 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine | |||||||||||||
| Medical condition: Migraine | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) PT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-018077-31 | Sponsor Protocol Number: 012010 | Start Date*: 2010-11-25 |
| Sponsor Name:St. Anna Kinderkrebsforschung/CCRI | ||
| Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA | ||
| Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) ES (Ongoing) DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) PL (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-005036-28 | Sponsor Protocol Number: 2012/41 | Start Date*: 2013-04-12 | |||||||||||
| Sponsor Name:CENTRE ANTOINE LACASSAGNE | |||||||||||||
| Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate | |||||||||||||
| Medical condition: Prostate cancer metastatic | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000600-29 | Sponsor Protocol Number: UX023-CL301 | Start Date*: 2016-09-15 | |||||||||||
| Sponsor Name:Ultragenyx Pharmaceuticals Inc | |||||||||||||
| Full Title: A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
| Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, defective bone mineralisation, and impaired growth plate or endochondral ossification caused by inactivating mutations in t... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) IE (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003410-41 | Sponsor Protocol Number: AOP18007 | Start Date*: 2014-01-13 | |||||||||||
| Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
| Full Title: A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TE... | |||||||||||||
| Medical condition: male or female patients with confirmed diagnosis of Essential Thrombocythemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) LT (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.